Lower Dose of Abiraterone Acetate Proves Effective in Treating Prostate Cancer
A new study demonstrates that a lower, 500 mg daily dose of abiraterone acetate is as effective and safe as the standard dose for treating metastatic prostate cancer, potentially reducing side effects and costs.
Recent research conducted by scientists from the National University of Singapore (NUS) and the National University Hospital (NUH) suggests that a reduced dose of abiraterone acetate (AA), a drug commonly used in prostate cancer therapy, can be just as effective and safe as the standard high dose. Traditionally, the treatment involves a daily dose of 1000 mg, which can cause significant side effects and increase costs for patients. This new study explored whether a 500 mg daily dose, taken on an empty stomach, could deliver comparable therapeutic benefits.
The study involved nine men with metastatic prostate cancer. Results showed that patients receiving the lower dose experienced significant reductions in prostate-specific antigen (PSA) levels, a key marker of tumor activity, indicating effective cancer suppression. Both patient data and pharmacological modeling demonstrated that even at half the usual dosage, over 80% of the drug’s target enzyme, CYP17A1, remained inhibited, supporting the therapy's potency.
Findings were published in the journal Cancer Communications. The research indicates that lowering the dosage could reduce adverse side effects, lower treatment costs, and improve patient adherence. This approach could particularly benefit elderly patients or those with limited financial resources, making prostate cancer management more accessible.
Lead researcher Professor Eric Chan highlighted that all patients on the 500 mg regimen showed PSA reductions within 12 weeks, with more than 75% experiencing a decrease of 50% or more. The safety profile was favorable, with little to no significant side effects reported. The team has initiated larger, long-term trials to further validate these promising results.
This innovative, model-informed dosing strategy offers a potential shift in prostate cancer treatment, emphasizing cost-effectiveness and safety without compromising efficacy. Source: https://medicalxpress.com/news/2025-07-dose-abiraterone-acetate-effective-prostate.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Recall of Ritz Peanut Butter Crackers Due to Labeling Error
A nationwide recall of Ritz Peanut Butter Crackers has been issued due to labeling errors that pose serious allergy risks. Consumers with peanut allergies should discard affected products immediately.
New Insights into Molecular Mechanisms Supporting Long-Term Immunity
Scientists have identified that the protein SATB1 is essential for maintaining the stem-like qualities of T-cells, supporting long-term immunity in infections and cancer. This discovery offers potential for new immunotherapy strategies.
New Research Finds One in Twelve Patients with Multiple Cancers Have Inherited Genetic Risks
A groundbreaking study reveals that 1 in 12 patients with multiple cancers carry inherited genetic mutations, highlighting the need for broader genetic screening to improve cancer management and prevention.
Heart Arrhythmia Drug Repurposed to Combat Antibiotic-Resistant Bacteria
Research from Emory University has discovered that the heart arrhythmia medication fendiline can be repurposed to kill antibiotic-resistant bacteria, offering new hope for treating difficult hospital infections.